# A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection

> **NCT03222583** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 546 (actual)

## Conditions studied

- Hepatitis C Virus (HCV)

## Interventions

- **DRUG:** Placebo
- **DRUG:** Glecaprevir/Pibrentasvir

## Key facts

- **NCT ID:** NCT03222583
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-04
- **Primary completion:** 2018-10-18
- **Final completion:** 2019-02-15
- **Target enrollment:** 546 (ACTUAL)
- **Last updated:** 2019-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03222583

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03222583, "A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03222583. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*